Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study.

Benjamin Maasoumy,Patrick Ingiliz,Christoph D Spinner,Christiane Cordes,Hans-Jürgen Stellbrink,Julian Schulze Zur Wiesch,Stephan M Schneeweiß,Katja Deterding,Tobias Müller,Julia Kahlhöfer,Petra Dörge,Maria von Karpowitz,Michael P Manns,Heiner Wedemeyer,Markus Cornberg

JHEP reports : innovation in hepatology（2023）

引用 1|浏览37

暂无评分

摘要

The HepNet acute HCV-V study (NCT03818308), an investigator-initiated, single-arm, multicenter pilot study, demonstrates the efficacy and safety of 8 weeks of daily treatment with the fixed-dose combination sofosbuvir/velpatasvir (400/100 mg) in patients with acute hepatitis C virus (HCV) infection. All patients who completed therapy and were followed-up achieved sustained virologic response. Thus, early treatment with SOF/VEL which might effectively prevent the spread of HCV in high-risk groups can be recommended for patients with acute HCV monoinfection.

查看译文

关键词

ALT, alanine aminotransferase,HCV, hepatitis C virus,ITT, intention-to-treat,LLOQ, lower limit of quantification,PP, per protocol,SVR, sustained virologic response,ULN, upper limit of normal,acute HCV infection,direct-acting antivirals,hepatitis C elimination,recently acquired infection

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要